The pleiotropic factor Y-box binding protein-1 enhances the anti-proliferative efficacy of 4-hydroxytamoxifen and fulvestrant on breast cancer cells in vitro

Purpose of investigation: The pleiotropic factor Y-box binding protein-1 (YB-1) is clinically correlated with breast cancer patients’ poor outcome. Due to the intereference of YB-1 with the estrogen receptor, the authors examined the antiproliferative efficacy of 4-hydroxytamoxifen (4-OHT) and fulvestrant (FUL) in the presence of low and high levels of YB-1. Materials and Methods: The human breast cancer cell line MCF-7 was transfected to overexpress YB-1 protein. 4-OHT and FUL incubation experiments were performed and cell growth behaviour of YB-1 overexpressing MCF-7 cells were compared to unmodified MCF-7 cells expressing endogenous YB-1 levels. Results: The incubation of MCF-7 cells with 100 nM 4-OHT and 1 nM FUL over a period of 120 hours clearly demonstrated the antiproliferative properties of both antiestrogens as expected. Notably, high levels of YB-1 led to an increase of antiproliferative properties in the presence of 4-OHT and FUL. Conclusion: The data presented here demonstrated YB-1 enhances the antiestrogenic efficacy of 4-OHT and FUL. Thus, the group of high level YB-1 mamma carcinoma patients might increasingly benefit from endocrine therapy.

Breast cancer; YB-1; Endocrine therapy; 4-hydroxytamoxifen; Fulvestrant

[1] Popp S.L., Joffroy C., Stope M.B., Buck M.B., Fritz P., Knabbe C.: “Antiestrogens suppress effects of transforming growth factor-beta in breast cancer cells via the signaling axis estrogen receptor-alpha and Y-box Binding Protein-1”. Anticancer Res., 2013, 33, 2473.

[2] Mylona E., Melissaris S., Giannopoulou I., Theohari I., Papadimitriou C., Keramopoulos A., Nakopoulou L.: “Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse”. Eur. J. Surg. Oncol., 2014, 40, 289.

[3] Zhang Y., Reng S.R., Wang L., Lu L., Zhao Z.H., Zhang Z.K., et al.:"Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy”. Med. Oncol., 2012, 29, 1992.

[4] Oda Y., Ohishi Y., Basaki Y., Kobayashi H., Hirakawa T., Wake N., et al.: “Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and Pglycoprotein expression”. Cancer Sci., 2007, 98, 1020.

[5] Gimenez-Bonafe P., Fedoruk M.N., Whitmore T.G., Akbari M., Ralph J.L., Ettinger S., et al.: “YB-1 is upregulated during prostate cancer tumor progression and increases Pglycoprotein activity”. Prostate, 2004, 59, 337.

[6] Eliseeva I.A., Kim E.R., Guryanov S.G., Ovchinnikov L.P., Lyabin D.N.: “Y-box-binding protein 1 (YB-1) and its functions”. Biochemistry Mosc., 2011, 76, 1402.

[7] Wu J., Lee C., Yokom D., Jiang H., Cheang M.C., Yorida E., et al.: “Disruption of the Y-box binding protein-1 results in suppression of the epi- dermal growth factor receptor and HER-2”. Cancer Res., 2006, 66, 4872.

[8] Fujii T., Kawahara A., Basaki Y., Hattori S., Nakashima K., Nakano K., et al.: “Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers”. Cancer Res., 2008, 68, 1504.

[9] Lage H., Surowiak P., Holm P.S.: “YB-1 as a potential target in cancer therapy”. Pathologe, 2008, 29, 187.

[10] Kaufmann M., von Minckwitz G., Bergh J., Conte P.F., Darby S., Eiermann W., et al.: “Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades”. Arch. Gynecol. Obstet., 2013, 288, 1203.

[11] Li C., Sun Z., Gui S., Liu F., Zhang Y.: “Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism”. Neuro. Endocrinol. Lett., 2009, 30, 268.

[12] Bekaii-Saab T.S., Perloff M.D., Weemhoff J.L., Greenblatt D.J., von Moltke L.L.: “Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A”. Biopharm. Drug. Dispos., 2004, 25, 283.

[13] Ito T., Kamijo S., Izumi H., Kohno K., Amano J., Ito K.: “Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer”. Breast Cancer Res. Treat., 2012, 133, 145.